Dare Bioscience Reports Q3 2025 Results and Plans December Launch of Sildenafil Cream
Daré Bioscience Inc. reported Q3 2025 financial results and announced the December launch of DARE to PLAY™ Sildenafil Cream via the 503B compounding pathway. The company also reported positive interim DSMB results for the Ovaprene® Phase 3 study and advancements in grant-funded programs. Daré plans to commercialize four women's health products over the next two years, including DARE to RESTORE™ vaginal probiotics and DARE to RECLAIM™ hormone therapy. Investors are encouraged to review the company's Form 10-Q for detailed financial information.
Daré Bioscience Inc. reported its financial results for the third quarter ended September 30, 2025, and provided a corporate update. The company announced that DARE to PLAY™ Sildenafil Cream is on track to launch before year-end via the 503B compounding pathway, which is expected to generate near-term product revenue. The company also reported a positive interim DSMB outcome for the Ovaprene® Phase 3 study, supporting continued enrollment. Daré Bioscience highlighted the advancement of multiple grant-funded programs, including those addressing HPV and long-acting as well as non-hormonal contraception. The company expects four women’s health products to become commercially available over the next two years. Following the launch of DARE to PLAY™ Sildenafil Cream, commercialization of DARE to RESTORE™ vaginal probiotics in the consumer health market is targeted, and DARE to RECLAIM™ monthly hormone therapy via the 503B compounding pathway is planned for early 2027. Daré Bioscience stated that DARE to RECLAIM™ will establish its entry into the estimated $4.5 billion compounded hormone therapy market while the company continues to pursue FDA approval opportunities. The company encouraged investors to review its Form 10-Q for detailed financial information, results of operations, liquidity, capital resources, and risk factors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574724-en) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
